Headline News
Neurocrine Biosciences shares are trading lower after the company reported worse-than-expected Q3 sales results. Following earnings, multiple firms lowered their respective price targets on the stock.
by Asad | Nov 2, 2021 | Uncategorized | 0 comments

Recent Comments